Company Overview
About Alto Neuroscience
Alto Neuroscience is a publicly-listed (Nasdaq: ANRO) clinical-stage biotech applying biomarker-stratified patient selection to psychiatry — matching patients to drugs based on brain biology rather than symptom checklists that have historically produced inconsistent treatment outcomes. The company raised a $120 million PIPE in 2026 to fund Phase 2b development of ALTO-207, a fixed-dose combination of pramipexole and ondansetron for treatment-resistant depression (TRD). The FDA has granted Fast Track designation for ALTO-101, and Alto has four clinical data readouts expected through 2027.
Business Model & Competitive Advantage
Treatment-resistant depression affects approximately 3 million Americans who fail two or more adequate antidepressant trials. Existing treatments for TRD (ketamine/esketamine, ECT, TMS) are effective but require clinic visits and carry significant side effect profiles. Alto's oral fixed-dose combination targeting TRD represents a potentially more accessible outpatient treatment option.
Competitive Landscape 2025–2026
The biomarker stratification approach is Alto's scientific differentiator: conventional antidepressant trials enroll unselected patients and achieve 30-40% response rates. Alto's platform uses neuroimaging, EEG, and genetic biomarkers to identify the 30-40% of patients most likely to respond to each specific drug mechanism — enabling clinical trials with higher response rates in the selected subpopulation and regulatory filings for a defined biomarker-positive indication.
Open Positions
Reddit Discussions
Key Differentiators
Emerging Innovator
Alto Neuroscience is an emerging player bringing innovative solutions to the BioTech market.
Growth Stage
Alto Neuroscience has achieved $120M in revenue, demonstrating strong product-market fit.
Frequently Asked Questions
Not So Random Others
a2z Radiology AI
a2z Radiology AI has developed a whole-body CT analysis platform that simultaneously screens for over 24 medical conditions across a single CT scan, including incidental cancers, coronary artery disea
Adept AI
Adept AI was founded in 2022 by a team of former OpenAI, DeepMind, and Google Brain researchers to build AI that can take actions on computers — navigating software interfaces, filling forms, and exec
Duckie
Duckie is a San Francisco-based AI customer support platform — backed by Y Combinator (W24) with $500,000 in funding from Y Combinator, Andreessen Horowitz, Greylock, KungHo Fund, Netflix, and 5 addit
Plenty
Plenty is a San Francisco-based indoor vertical farming company that uses AI, machine learning, and robotics to grow leafy greens and other produce in controlled indoor environments. The company has r
Oura
Oura is the maker of the Oura Ring, a premium smart ring that tracks sleep, recovery, readiness, and health metrics through continuous biometric sensing. The company raised $900 million in Series E fi
Nira Energy
Nira Energy is a Denver-based renewable energy software company providing grid capacity mapping and interconnection analysis tools that help solar, battery storage, and data center developers identify
Compare Alto Neuroscience with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Alto Neuroscience? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Alto Neuroscience Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Alto Neuroscience vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →